Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

被引：63

作者：

Liu, Hongtao ^{[1
]}

Johnson, Jeffrey L. ^{[2
,3
]}

Koval, Greg ^{[1
]}

Malnassy, Greg ^{[1
]}

Sher, Dorie ^{[1
]}

Damon, Lloyd E. ^{[4
]}

Hsi, Eric D. ^{[5
]}

Bucci, Donna Marie ^{[6
]}

Linker, Charles A. ^{[4
]}

Cheson, Bruce D. ^{[7
]}

Stock, Wendy ^{[1
]}

机构：

[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[2] Duke Univ, Med Ctr, Durham, NC USA

[3] CALGB Stat & Data Ctr, Durham, NC USA

[4] Univ Calif San Francisco, San Francisco, CA 94143 USA

[5] Cleveland Clin, Cleveland, OH 44106 USA

[6] Ohio State Univ, Columbus, OH 43210 USA

[7] Georgetown Univ Hosp, CALGB, Boston, MA USA

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 04期

关键词：

minimal residual disease; progression-free survival; MCL; induction; chemotherapy; DOSE SEQUENTIAL CHEMOTHERAPY; LONG-TERM REMISSION; MARROW-TRANSPLANTATION; MOLECULAR REMISSION; INDOLENT LYMPHOMA; HYPER-CVAD; RITUXIMAB; MULTICENTER; MCL; BORTEZOMIB;

D O I：

10.3324/haematol.2011.050203

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background In the present study, the prognostic impact of minimal residual disease during treatment on time to progression and overall survival was analyzed prospectively in patients with mantle cell lymphoma treated on the Cancer and Leukemia Group B 59909 clinical trial. Design and Methods Peripheral blood and bone marrow samples were collected during different phases of the Cancer and Leukemia Group B 59909 study for minimal residual disease analysis. Minimal residual disease status was determined by quantitative polymerase chain reaction of IgH and/or BCL-1/JH gene rearrangement. Correlation of minimal residual disease status with time to progression and overall survival was determined. In multivariable analysis, minimal residual disease, and other risk factors were correlated with time to progression. Results Thirty-nine patients had evaluable, sequential peripheral blood and bone marrow samples for minimal residual disease analysis. Using peripheral blood monitoring, 18 of 39 (46%) achieved molecular remission following induction therapy. The molecular remission rate increased from 46 to 74% after one course of intensification therapy. Twelve of 21 minimal residual disease positive patients (57%) progressed within three years of follow up compared to 4 of 18 (22%) molecular remission patients (P=0.049). Detection of minimal residual disease following induction therapy predicted disease progression with a hazard ratio of 3.7 (P=0.016). The 3-year probability of time to progression among those who were in molecular remission after induction chemotherapy was 82% compared to 48% in patients with detectable minimal residual disease. The prediction of time to progression by post-induction minimal residual disease was independent of other prognostic factors in multivariable analysis. Conclusions Detection of minimal residual disease following induction immunochemotherapy was an independent predictor of time to progression following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma.

引用

页码：579 / 585

页数：7

共 26 条

[1] Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma [J].

Andersen, Niels S. ;

Pedersen, Lone B. ;

Laurell, Anna ;

Elonen, Erkki ;

Kolstad, Arne ;

Boesen, Anne Marie ;

Pedersen, Lars M. ;

Lauritzsen, Grete F. ;

Ekanger, Roald ;

Nilsson-Ehle, Herman ;

Nordstrom, Marie ;

Freden, Susanne ;

Jerkeman, Mats ;

Eriksson, Mikael ;

Vaart, Jaan ;

Malmer, Beatrice ;

Geisler, Christian H. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4365-4370

[2] Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease [J].

Andersen, NS ;

Donovan, JW ;

Borus, JS ;

Poor, CM ;

Neuberg, D ;

Aster, JC ;

Nadler, LM ;

Freedman, AS ;

Gribben, JG .

BLOOD, 1997, 90 (10) :4212-4221

[3] Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation [J].

Cook, Gordon ;

Smith, Graeme M. ;

Kirkland, Keiren ;

Lee, Julia ;

Pearce, Rachel ;

Thomson, Kirsty ;

Morris, Emma ;

Orchard, Kim ;

Rule, Simon ;

Russell, Nigel ;

Craddock, Charles ;

Marks, David I. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (10) :1419-1427

[4] Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes [J].

Corradini, P ;

Ladetto, M ;

Zallio, F ;

Astolfi, M ;

Rizzo, E ;

Sametti, S ;

Cuttica, A ;

Rosato, R ;

Farina, L ;

Boccadoro, M ;

Benedetti, F ;

Pileri, A ;

Tarella, C .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1460-1468

[5]

COX DR, 1972, J R STAT SOC B, V34, P187

[6] Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 [J].

Damon, Lloyd E. ;

Johnson, Jeffrey L. ;

Niedzwiecki, Donna ;

Cheson, Bruce D. ;

Hurd, David D. ;

Bartlett, Nancy L. ;

LaCasce, Ann S. ;

Blum, Kristie A. ;

Byrd, John C. ;

Kelly, Michael ;

Stock, Wendy ;

Linker, Charles A. ;

Canellos, George P. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6101-6108

[7]

Donovan JW, 2000, BLOOD, V95, P2651

[8] Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network [J].

Dreyling, M ;

Lenz, G ;

Hoster, E ;

Van Hoof, A ;

Gisselbrecht, C ;

Schmits, R ;

Metzner, B ;

Truemper, L ;

Reiser, M ;

Steinhauer, H ;

Boiron, JM ;

Boogaerts, MA ;

Aldaoud, A ;

Silingardi, V ;

Kluin-Nelemans, HC ;

Hasford, J ;

Parwaresch, R ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2005, 105 (07) :2677-2684

[9] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J].

Fisher, Richard I. ;

Bernstein, Steven H. ;

Kahl, Brad S. ;

Djulbegovic, Benjamin ;

Robertson, Michael J. ;

de Vos, Sven ;

Epner, Elliot ;

Krishnan, Amrita ;

Leonard, John P. ;

Lonial, Sagar ;

Stadtmauer, Edward A. ;

O'Connor, Owen A. ;

Shi, Hongliang ;

Boral, Anthony L. ;

Goy, Andre .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4867-4874

[10] Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma [J].

Freedman, AS ;

Neuberg, D ;

Mauch, P ;

Soiffer, RJ ;

Anderson, KC ;

Fisher, DC ;

Schlossman, R ;

Alyea, EP ;

Takvorian, T ;

Jallow, H ;

Kuhlman, C ;

Ritz, J ;

Nader, LM ;

Gribben, JG .

BLOOD, 1999, 94 (10) :3325-3333

← 1 2 3 →